ABBOTT-CLOPIDOGREL TABLET

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

CLOPIDOGREL (CLOPIDOGREL BISULFATE)

Inapatikana kutoka:

ABBOTT LABORATORIES, LIMITED

ATC kanuni:

B01AC04

INN (Jina la Kimataifa):

CLOPIDOGREL

Kipimo:

75MG

Dawa fomu:

TABLET

Tungo:

CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

100/500

Dawa ya aina:

Prescription

Eneo la matibabu:

PLATELET AGGREGATION INHIBITORS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0134440001; AHFS:

Idhini hali ya:

CANCELLED POST MARKET

Idhini ya tarehe:

2015-12-31

Tabia za bidhaa

_ _
_Abbott-Clopidogrel Product Monograph _
_Page 1 of 52 _
_ _
_ _
PRODUCT MONOGRAPH
PR
ABBOTT-CLOPIDOGREL
Clopidogrel Tablets USP
75 mg clopidogrel, as clopidogrel bisulfate
Platelet Aggregation Inhibitor
Abbott Laboratories, Limited
8401 Trans-Canada Highway
Saint-Laurent, Quebec
H4S 1Z1
Date of Revision:
November 27, 2014
Submission Control No.: 179756
_ _
_Abbott-Clopidogrel Product Monograph _
_Page 2 of 52 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................19
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................24
SPECIAL HANDLING INSTRUCTIONS
.......................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................26
PHARMACEUTICAL INFORMATION
.........................................................